PL3307727T3 - Heterocykliczne inhibitory erk1 i erk2 oraz ich zastosowanie w leczeniu nowotworów - Google Patents
Heterocykliczne inhibitory erk1 i erk2 oraz ich zastosowanie w leczeniu nowotworówInfo
- Publication number
- PL3307727T3 PL3307727T3 PL16741411.9T PL16741411T PL3307727T3 PL 3307727 T3 PL3307727 T3 PL 3307727T3 PL 16741411 T PL16741411 T PL 16741411T PL 3307727 T3 PL3307727 T3 PL 3307727T3
- Authority
- PL
- Poland
- Prior art keywords
- erk2
- erk1
- cancer
- treatment
- heterocyclic inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175756P | 2015-06-15 | 2015-06-15 | |
| PCT/US2016/037697 WO2016205418A1 (en) | 2015-06-15 | 2016-06-15 | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3307727T3 true PL3307727T3 (pl) | 2024-07-08 |
Family
ID=56497830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16741411.9T PL3307727T3 (pl) | 2015-06-15 | 2016-06-15 | Heterocykliczne inhibitory erk1 i erk2 oraz ich zastosowanie w leczeniu nowotworów |
| PL21156048.7T PL3842429T3 (pl) | 2015-06-15 | 2016-06-15 | Heterocykliczne inhibitory ERK1 i ERK2 oraz ich zastosowanie w leczeniu nowotworu złośliwego |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21156048.7T PL3842429T3 (pl) | 2015-06-15 | 2016-06-15 | Heterocykliczne inhibitory ERK1 i ERK2 oraz ich zastosowanie w leczeniu nowotworu złośliwego |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US10751332B2 (pl) |
| EP (2) | EP3307727B1 (pl) |
| JP (2) | JP6909729B2 (pl) |
| KR (2) | KR102644798B1 (pl) |
| CN (2) | CN107922387B (pl) |
| AU (2) | AU2016280717C1 (pl) |
| BR (1) | BR112017026159A2 (pl) |
| CA (1) | CA2986587C (pl) |
| DK (2) | DK3307727T3 (pl) |
| ES (2) | ES2930050T3 (pl) |
| FI (1) | FI3307727T3 (pl) |
| IL (1) | IL255613B (pl) |
| MX (2) | MX388641B (pl) |
| PL (2) | PL3307727T3 (pl) |
| PT (2) | PT3842429T (pl) |
| RU (1) | RU2017139727A (pl) |
| WO (1) | WO2016205418A1 (pl) |
| ZA (1) | ZA201707526B (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3307727T3 (pl) * | 2015-06-15 | 2024-07-08 | Asana Biosciences, Llc | Heterocykliczne inhibitory erk1 i erk2 oraz ich zastosowanie w leczeniu nowotworów |
| ES2989326T3 (es) | 2015-10-21 | 2024-11-26 | Otsuka Pharma Co Ltd | Compuestos de benzolactama como inhibidores de la proteína cinasa |
| GB201706327D0 (en) * | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| AU2018269982B2 (en) * | 2017-05-16 | 2024-06-13 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical BRAF mutations |
| AU2019280356B2 (en) * | 2018-06-08 | 2022-09-29 | Betta Pharmaceuticals Co., Ltd | ERK inhibitor and use thereof |
| CN109608444B (zh) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 |
| JP2022527744A (ja) | 2019-03-28 | 2022-06-06 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | チエノ複素環式誘導体、この誘導体のための調製方法及び医療に関するこの誘導体の使用 |
| AU2020251621A1 (en) * | 2019-03-29 | 2021-11-04 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine |
| JP7738550B2 (ja) * | 2019-10-28 | 2025-09-12 | アサナ バイオサイエンシズ，リミティド ライアビリティ カンパニー | Ｅｒｋ１およびｅｒｋ２の複素環式阻害剤の使用のための改善された方法、キット、組成物、ならびに投与レジメン |
| CN111620860B (zh) * | 2020-06-23 | 2023-02-03 | 济南健丰化工有限公司 | 一种福瑞塞替的制备方法 |
| CN114315837B (zh) * | 2020-09-29 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种erk抑制剂的结晶形式及其制备方法 |
| AU2021354821A1 (en) * | 2020-09-29 | 2023-06-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystal form of pyrrolo heterocyclic derivative and preparation method therefor |
| EP4322956A4 (en) * | 2021-04-16 | 2025-03-19 | Erasca, Inc. | Uses of heterocyclic inhibitors of erk1/2 |
| WO2022271919A1 (en) * | 2021-06-24 | 2022-12-29 | Erasca, Inc. | Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy |
| WO2022271939A1 (en) * | 2021-06-24 | 2022-12-29 | Erasca, Inc. | Erk1/2 and cdk4/6 inhibitors combination therapy |
| US20240285625A1 (en) * | 2021-06-24 | 2024-08-29 | Erasca, Inc. | Erk1/2 and kras g12c inhibitors combination therapy |
| MX2023015298A (es) * | 2021-06-24 | 2024-03-20 | Erasca Inc | Terapia de combinación de inhibidores de erk1/2 y shp2. |
| CN118871442A (zh) * | 2022-03-28 | 2024-10-29 | 江苏恒瑞医药股份有限公司 | 一种吡咯并杂环类衍生物的富马酸盐的晶型及其制备方法 |
| WO2024064690A1 (en) * | 2022-09-20 | 2024-03-28 | Erasca, Inc. | Erk1/2 inhibitor polymorph forms |
| EP4646209A1 (en) * | 2023-01-06 | 2025-11-12 | Erasca, Inc. | Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1319849B1 (it) | 2000-02-18 | 2003-11-03 | Angelo Dotta | Cerotto in confezione ad apertura rapida e mezzi per la realizzazionedella stessa. |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| US6743941B2 (en) | 2001-06-15 | 2004-06-01 | Aventis Pharma Deutschland Gmbh | Process for the production of piperidine derivatives |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| EP1697375A2 (en) | 2003-12-02 | 2006-09-06 | Vertex Pharmaceuticals Incorporated | Heterocyclic protein kinase inhibitors and uses thereof |
| US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
| WO2005113546A1 (en) * | 2004-05-14 | 2005-12-01 | Vertex Pharmaceuticals, Incorporated | Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors |
| EP1833820A1 (en) * | 2004-12-23 | 2007-09-19 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of erk protein kinase and uses therof |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| JP5740409B2 (ja) * | 2009-11-13 | 2015-06-24 | ジェノスコ | キナーゼ阻害剤 |
| US8691861B2 (en) | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| US9227969B2 (en) * | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| PL3307727T3 (pl) | 2015-06-15 | 2024-07-08 | Asana Biosciences, Llc | Heterocykliczne inhibitory erk1 i erk2 oraz ich zastosowanie w leczeniu nowotworów |
| CN109661228A (zh) | 2016-06-20 | 2019-04-19 | 库拉肿瘤学公司 | 用erk抑制剂治疗鳞状细胞癌 |
| TW202023556A (zh) | 2018-08-27 | 2020-07-01 | 美商庫拉腫瘤技術股份有限公司 | 以mapk路徑抑制劑治療腺癌 |
| JP7738550B2 (ja) | 2019-10-28 | 2025-09-12 | アサナ バイオサイエンシズ，リミティド ライアビリティ カンパニー | Ｅｒｋ１およびｅｒｋ２の複素環式阻害剤の使用のための改善された方法、キット、組成物、ならびに投与レジメン |
| EP4322956A4 (en) | 2021-04-16 | 2025-03-19 | Erasca, Inc. | Uses of heterocyclic inhibitors of erk1/2 |
-
2016
- 2016-06-15 PL PL16741411.9T patent/PL3307727T3/pl unknown
- 2016-06-15 CA CA2986587A patent/CA2986587C/en active Active
- 2016-06-15 EP EP16741411.9A patent/EP3307727B1/en active Active
- 2016-06-15 DK DK16741411.9T patent/DK3307727T3/da active
- 2016-06-15 MX MX2017014584A patent/MX388641B/es unknown
- 2016-06-15 PT PT211560487T patent/PT3842429T/pt unknown
- 2016-06-15 CN CN201680031963.5A patent/CN107922387B/zh active Active
- 2016-06-15 PL PL21156048.7T patent/PL3842429T3/pl unknown
- 2016-06-15 BR BR112017026159-6A patent/BR112017026159A2/pt not_active Application Discontinuation
- 2016-06-15 RU RU2017139727A patent/RU2017139727A/ru not_active Application Discontinuation
- 2016-06-15 CN CN202110399513.4A patent/CN113200961B/zh active Active
- 2016-06-15 AU AU2016280717A patent/AU2016280717C1/en active Active
- 2016-06-15 WO PCT/US2016/037697 patent/WO2016205418A1/en not_active Ceased
- 2016-06-15 JP JP2017559575A patent/JP6909729B2/ja active Active
- 2016-06-15 US US15/183,504 patent/US10751332B2/en active Active
- 2016-06-15 EP EP21156048.7A patent/EP3842429B1/en active Active
- 2016-06-15 FI FIEP16741411.9T patent/FI3307727T3/fi active
- 2016-06-15 ES ES21156048T patent/ES2930050T3/es active Active
- 2016-06-15 PT PT167414119T patent/PT3307727T/pt unknown
- 2016-06-15 US US15/183,486 patent/US9896445B2/en active Active
- 2016-06-15 DK DK21156048.7T patent/DK3842429T3/da active
- 2016-06-15 KR KR1020217005104A patent/KR102644798B1/ko active Active
- 2016-06-15 KR KR1020177034157A patent/KR102644788B1/ko active Active
- 2016-06-15 ES ES16741411T patent/ES2968007T3/es active Active
-
2017
- 2017-09-01 US US15/694,124 patent/US10471051B2/en active Active
- 2017-11-07 ZA ZA2017/07526A patent/ZA201707526B/en unknown
- 2017-11-12 IL IL255613A patent/IL255613B/en active IP Right Grant
- 2017-11-14 MX MX2021000148A patent/MX2021000148A/es unknown
-
2020
- 2020-02-13 US US16/790,082 patent/US11103491B2/en active Active
- 2020-11-19 AU AU2020273302A patent/AU2020273302B2/en active Active
-
2021
- 2021-03-16 JP JP2021042239A patent/JP7093438B2/ja active Active
- 2021-07-06 US US17/368,559 patent/US11925629B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255613B (en) | Heterocyclic inhibitors of erk1 and erk2 and their use in cancer therapy | |
| IL272948B1 (en) | enpp1 inhibitors and their use for cancer treatment | |
| IL256874B (en) | Immune checkpoint suppressors for use in the treatment of blood-borne cancers | |
| IL267455A (en) | Phosphodiesterase inhibitors and methods of treating bacteria | |
| IL259441B1 (en) | Materials and methods for the treatment of titin-based myopathies and other titinopathy | |
| IL262387B (en) | Arginase inhibitors and treatment applications thereof | |
| PT3362448T (pt) | Novos compostos inibidores da interação yap/taz-tead e sua utilização no tratamento do mesotelioma maligno | |
| SI3285803T1 (sl) | Postopki za zdravljenje in preprečevanje migrenskega glavobola | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| IL264451B1 (en) | A combination of abt-199 and achmetalstat for the treatment of aml | |
| LT3371152T (lt) | Kompozicijos, apimančios lizinui specifinės demetilazės-1 inhibitorių, turinčios pirimidino žiedą, ir jų panaudojimas vėžio gydymui | |
| PL3240777T3 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| IL250484B (en) | Heterovesicular compounds and their use in the treatment of tuberculosis | |
| ZA201904966B (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| GB201514021D0 (en) | Novel Pyridines and their use in the treatment of cancer | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| ZA201904967B (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| IL263804A (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| PL3362450T3 (pl) | N1 i n7-podstawione pochodne sybiriliny oraz ich zastosowania jako inhibitory nekroptozy komórkowej | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer | |
| IL271211B1 (en) | Acetyl leucine for use in the treatment of migraine | |
| GB201605127D0 (en) | Composition and methods of treatment | |
| GB201710491D0 (en) | Composition and methods of treatment | |
| ZA201808008B (en) | Arginase inhibitors and their therapeutic applications |